Ischemic Heart Disease: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered DUTOPROL, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1–2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, DUTOPROL or beta-blocking agent administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue DUTOPROL therapy abruptly even in patients treated only for hypertension.
(metoprolol succinate extended release/hydrochlorothiazide)
Tablet, Film Coated
DUTOPROL™ (metoprolol succinate extended release/hydrochlorothiazide) combines a beta1-selective (cardioselective) adrenoceptor blocking agent and a diuretic, hydrochlorothiazide.
DUTOPROL is indicated for the management of hypertension. The fixed-dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION).
Media Articles Related to Dutoprol (Metoprolol / Hydrochlorothiazide)
Low levels of hormone in African-Americans may increase hypertension
Source: Endocrinology News From Medical News Today [2015.06.11]
Although hypertension is more common in African-Americans, they have significantly lower levels of a hormone produced in response to cardiac stress than white and Hispanic individuals, a finding that...
Source: MedicineNet Alcohol Abuse and Alcoholism Specialty [2015.05.29]
Title: Portal Hypertension
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 5/29/2015 12:00:00 AM
New data show need for improved monitoring for pulmonary hypertension following pulmonary embolism
Source: Hypertension News From Medical News Today [2015.05.20]
Results from a retrospective cohort study presented at the American Thoracic Society (ATS) 2015 International Conference in Denver found that the incidence of pulmonary hypertension (PH) among...
Source: MedicineNet Fainting Specialty [2015.02.19]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 2/19/2015 12:00:00 AM
Picture of Hypertension
Source: MedicineNet Renal Artery Stenosis Specialty [2014.12.09]
Title: Picture of Hypertension
Created: 2/3/2011 1:47:00 PM
Last Editorial Review: 12/9/2014 12:00:00 AM
Published Studies Related to Dutoprol (Metoprolol / Hydrochlorothiazide)
Factorial antihypertensive study of an extended-release metoprolol and hydrochlorothiazide combination. [2006.12]
BACKGROUND: To attain goal blood pressure (BP), many hypertensive patients require combination antihypertensive therapy. Thiazide diuretic/beta-blocker regimens lower BP, and clinical studies indicate that they reduce the risk for cardiovascular consequences of hypertension. Fixed-dose combination tablets can simplify multidrug treatment regimens... CONCLUSIONS: Extended-release metoprolol/hydrochlorothiazide is an effective antihypertensive combination that offers additive antihypertensive contributions from both components.
Blood pressure and aortic elastic properties--verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy. [1998.08]
The effects of 2 fixed antihypertensive combination drugs on blood pressure and aortic elastic properties were compared in 2 parallel groups. Twenty-six patients for 6 months received a calcium antagonist plus ACE inhibitor (verapamil SR 180 mg/trandolapril 1 mg (Vera/Tran)) and 25 patients a beta-adrenoceptor antagonist plus diuretic (metoprolol 100 mg/hydrochlorothiazide 12.5 mg (Meto/HCTZ))...
Page last updated: 2015-06-11